85 related articles for article (PubMed ID: 23668218)
21. Drug resistance in multiple myeloma: approaches to circumvention.
Dalton WS; Jove R
Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891
[TBL] [Abstract][Full Text] [Related]
22. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
23. [IgA multiple myeloma with adverse prognostic factors--a case report].
Kumiega B; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2009; 66(8):459-63. PubMed ID: 20043594
[TBL] [Abstract][Full Text] [Related]
24. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
[TBL] [Abstract][Full Text] [Related]
25. [Mantle cell lymphoma in the era of targeted-therapy-in-depth report on American Society of Hematology 53rd annual meeting].
Liang R; Shi YK; Han XH
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):690-2. PubMed ID: 23134877
[No Abstract] [Full Text] [Related]
26. PC cell-derived growth factor confers resistance to dexamethasone and promotes tumorigenesis in human multiple myeloma.
Wang W; Hayashi J; Serrero G
Clin Cancer Res; 2006 Jan; 12(1):49-56. PubMed ID: 16397023
[TBL] [Abstract][Full Text] [Related]
27. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
28. American Society of Hematology 2015 Annual Meeting.
Alexander W
P T; 2016 Feb; 41(2):120-5. PubMed ID: 26909003
[TBL] [Abstract][Full Text] [Related]
29. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
31. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
32. [Hotspot report of 56th American Society of Hematology Annual Meeting: Hodgkin lymphoma].
Wang F; Fan L; Xu W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):262-4. PubMed ID: 25854479
[No Abstract] [Full Text] [Related]
33. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
35. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
36. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
Yang HH; Ma MH; Vescio RA; Berenson JR
J Clin Oncol; 2003 Nov; 21(22):4239-47. PubMed ID: 14615454
[TBL] [Abstract][Full Text] [Related]
37. [Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells].
Zang MR; Li F; An G; Xie ZQ; Li CH; Yu Z; Xu Y; Qiu LG; Hao M
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(16):1100-3. PubMed ID: 22781767
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
39. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
Vallet S; Podar K
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S35-53. PubMed ID: 23768134
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib (Kryprolis) for multiple myeloma.
Med Lett Drugs Ther; 2012 Dec; 54(1406):103-4. PubMed ID: 23282792
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
